Phathom Pharmaceuticals (PHAT) Raw Materials (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has 4 years of Raw Materials data on file, last reported at $5.0 million in Q1 2026.

• On a quarterly basis, Raw Materials rose 248.79% year-over-year to $5.0 million in Q1 2026; TTM through Mar 2026 was $5.0 million, a 248.79% increase from a year earlier, with the FY2025 full-year figure at $4.1 million, up 134.88% from the prior year.
• Raw Materials for Q1 2026 stood at $5.0 million, up from $4.1 million in the prior quarter.
• Over the last five years, Raw Materials for PHAT reached as high as $5.0 million in Q1 2026 and fell as low as $111000.0 in Q2 2023.
• Historically, Raw Materials has averaged $1.6 million across 4 years, with a median of $1.2 million in 2024.
• Across the five-year window, Raw Materials soared 1717.12% in 2024 and tumbled 50.02% in 2025, its largest moves.
• Year by year, Raw Materials stood at $561000.0 in 2023, then surged by 208.2% to $1.7 million in 2024, then soared by 134.88% to $4.1 million in 2025, then climbed by 23.76% to $5.0 million in 2026.
• Per Business Quant data, the three most recent Raw Materials figures were $5.0 million in Q1 2026, $4.1 million in Q4 2025, and $1.0 million in Q3 2025.